Pulmonary defense and the human cathelicidin hCAP-18/LL-37

Hackett C: Innate immune activation as a broad-spectrum biodefense strategy: prospects and research challenges. J Allergy Clin Immunol 2003;112(4):686–694. Fluhr R, Kaplan-Levy RN: Plant disease resistance: commonality and novelty in multicellular innate immunity. Curr Top Microbiol Immunol 2002;270:23–46. Boman HG: Antibacterial peptides: basic facts and emerging concepts. J Intern Med 2003;254(3):197–215. Ganz T: Defensins: antimicrobial peptides of innate immunity. Nature Rev Immunol 2003;3(9):710–720. Larrick JW, Hirata M, Balint RF, et al.: Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun 1995;63(4):1291–1297. Gennaro R, Skerlavaj B, Romeo D: Purification, composition, and activity of two bactenecins, antibacterial peptides of bovine neutrophils. Infect Immun 1989;57(10): 3142–3146. Basanez G, Shinnar AE, Zimmerberg J: Interaction of hagfish cathelicidin antimicrobial peptides with model lipid membranes. FEBS Lett 2002;532(1–2):115–120. Gudmundsson GH, Agerberth B, Odeberg J, et al.: The human gene FALL 39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem 1996;238(2):325–332. Zanetti M, Gennaro R, Romeo D: Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett 1995; 374(1):1–5. Sorensen OE, Follin P, Johnsen AH, et al.: Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 2001;97(12):3951–3959. Sorensen OE, Gram L, Johnsen AH, et al.: Processing of seminal plasma hCAP-18 to ALL-38 by gastricsin: a novel mechanism of generating antimicrobial peptides in vagina. J Biol Chem 2003;278(31)28540–28546. Sorensen O, Cowland JB, Askaa J, Borregaard N: An ELISA for hCAP-18, the cathelicidin present in human neutrophils and plasma. J Immunol Methods 1997;206 (1–2):53–59. Carlsson G, Fasth A: Infantile genetic agranulocytosis, morbus Kostmann: presentation of six cases from the original “Kostmann family” and a review. Acta Paediatr 2001;90(7):757–764. Zanetti M: Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 2004;75(1):39–48. Marchini G, Lindow S, Brismar H, et al.: The newborn infant is protected by an innate antimicrobial barrier: peptide antibiotics are present in the skin and vernix caseosa. Br J Dermatol 2002;147(6):1127–1134. Sorensen O, Amljots K, Cowland JB, et al.: The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood 1997;90(7):2796–2803. Nagaoka I, Hirata M, Sugimoto K, et al.: Evaluation of the expression of human CAP18 gene during neutrophil maturation in the bone marrow. J Leukoc Biol 1998; 64(6):845–852. Tomasinsig L, Scocchi M, Di Loreto C, et al.: Inducible expression of an antimicrobial peptide of the innate immunity in polymorphonuclear leukocytes. J Leukoc Biol 2002;72(5):1003–1010. Ong PY, Ohtake T, Brandt C, et al.: Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347(15):1151–1160. Dorschner RA, Pestonjamasp VK, Tamakuwala S, et al.: Cutaneous injury induces the release of cathelicidin antimicrobial peptides active against group A Streptococcus. J Invest Dermatol 2001;117(1):91–97. Dorschner RA, Lin KH, Murakami M, Gallo RL: Neonatal skin in mice and humans expresses increased levels of antimicrobial peptides: innate immunity during development of the adaptive response. Pediatr Res 2003; 53(4):566–572. Wu H, Zhang G, Minton JE, et al.: Regulation of cathelicidin gene expression: induction by lipopolysaccharide, interleukin-6, retinoic acid, and Salmonella enterica serovar typhimurium infection. Infect Immun 2000; 68(10):5552–5558. Larrick JW, Hirata M, Zheng H, et al.: A novel granulocyte-derived peptide with lipopolysaccharide-neutralizing activity. J Immunol 1994;152(1):231–240. Kirikae T, Hirata M, Yamasu H, et al.: Protective effects of a human 18-kilodalton cationic antimicrobial protein (CAP18)-derived peptide against murine endotoxemia. Infect Immun 1998;66(5):1861–1868. Scott MG, Davidson DJ, Gold MR, et al.: The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol 2002; 169(7):3883–3891. Davidson DJ, Currie AJ, Reid GS, et al.: The cationic antimicrobial peptide LL-37 modulates dendritic cell differentiation and dendritic cell-induced T cell polarization. J Immunol 2004;172(2):1146–1156. Niyonsaba F, Someya A, Hirata M, et al.: Evaluation of the effects of peptide antibiotics human beta-defensins-1/−2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells. Eur J Immunol 2001;31(4):1066–1075. Heilborn JD, Nilsson MF, Kratz G, et al.: The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol 2003;120(3): 379–389. Dinarello CA: Biologic basis for interleukin-1 in disease. Blood 1996;87(6):2095–2147. Ganz T: Antimicrobial polypeptides in host defense of the respiratory tract. J Clin Invest 2002;109(6):693–697. Liu L, Roberts AA, Ganz T: By IL-1 signaling, monocyte-derived cells damatically enhance the epidermal antimicrobial response to lipopolysaccharide. J Immunol 2003;170(1):575–580. Perregaux DG, Bhavsar K, Contillo L, et al.: Tntimicrobial peptides initiate IL-1 β posttranslational processing: a novel role beyond innate immunity. J Immunol 2002;168(6):3024–3032. Elssner A, Duncan M, Kotur M, et al.: The human cathelicidin-derived peptide LL-37 induces secretion of IL-1 beta via transient ATP release and activation of the P2X receptor. J Immunol 2003;172(8):4987–4994. Chertov O, Michiel DF, Xu L, et al.: Identification of defensin-1, defensin-2, and CAP37/azurocidin as T-cell chemoattractant proteins released from interleukin-8-stimulated neutrophils. J Biol Chem 1996;271(6): 2935–2940. Agerberth B, Charo J, Werr J, et al.: The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000;96(9):3086–3093. De Yang, Chen Q, Schmidt AP, et al.: LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 2000;192(7):1069–1074. Niyonsaba F, Iwabuchi K, Someya A, et al.: A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis. Immunology 2002;106(1):20–26. Koczulla R, von Degenfeld G, Kupatt C, et al.: An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 2003;111(11):1665–1672. Turner J, Cho Y, Dinh NN, et al.: Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 1998;42(9): 2206–2214. Howell MD, Jones JF, Kisich KO, et al.: Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J Immunol 2004;172(3):1763–1767. Guthmiller JM, Vargas KG, Srikantha R, et al.: Susceptibilities of oral bacteria and yeast to mammalian cathelicidins. Antimicrob Agents Chemother 2001;45(11)3216–3219. Henzler Wildman KA, Dong-Kuk L, Ramamoorthy A: Mechanism of lipid bilayer disruption by the human antimicrobial peptide, LL-37. Biochemistry 2003;42(21): 6545–6558. Travis SM, Anderson NN, Forsyth WR, et al.: Bactericidal activity of mammalian cathelicidin-derived peptides. Infect Immun 2000;68(5):2748–2755. Saiman L, Tabibi S, Starner TD, et al.: Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis. Antimicrob Agents Chemother 2001;45(10):2838–2844. Sambri V, Marangoni A, Giacani L, et al.: Comparative in vitro activity of five cathelicidin-derived synthetic peptides against Leptospira, Borrelia and Treponema pallidum. J Antimicrob Chemother 2002;50(6):895–902. Zaiou M, Nizet V, Gallo RL: Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37) prosequence. J Invest Dermatol 2003; 120(5):810–816. Shafer WM, Qu X, Waring AJ, Lehrer RI: Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. Proc Natl Acad Sci USA 1998;95(4):1829–1833. Lysenko ES, Gould J, Bals R, et al.: Bacterial phosphorylcholine decreases susceptibility to the antimicrobial peptide LL-37/hCAP18 expressed in the upper respiratory tract. Infect Immun 2000;68(3):1664–1671. Schmidtchen A, Frick IM, Andersson E, et al.: Proteinases of common pathogenic bacteria degrade and inactivate the antibacterial peptide LL-37. Mol Microbiol 2002;46(1):157–168. Islan D, Bandholtz L, Nilsson J, et al.: Downregulation of bactericidal peptides in enteric infections: a novel immune escape mechanism with bacterial DNA as a potential regulaton. Nat Med 2001;7(2):180–185. Weiner DJ, Bucki R, Janmey PA: The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin. Am J Respir Cell Mol Biol 2003;28(6):738–745. Bals R, Wang X, Wu Z, et al.: Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in human lung. J Clin Invest 1998;102(5):874–880. Rennard S, Romberger D: Host defenses and pathogenesis. Semin Respir Infect 2000;15(1):7–13. Canner P: Clearance of particles from the human tracheobronchial tree. Clin Sci (Lond) 1980;59(2): 79–84. Welsh DA, Mason CM: Host defense in respiratory infections. Med Clin North Am 2001;85(6):1329–1347. Anderson RN, Smith BL: Deaths: leading causes for 2001. Natl Vital Stat Rep 2003;52(9):1–85. Travis SM, Conway BA, Zabner J, et al.: Activity of abundant antimicrobials of the human airway. Am J Respir Cell Mol Biol 1999;20(5):872–879. Singh PK, Jia HP, Wiles K, et al.: Production of beta-defensins by human airway epithelia. Proc Natl Acad Sci USA 1998;95(25):14961–14966. Bals R, Wang X, Zasloff M, Wilson JM: The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci USA 1998;95(16):9541–9546. Remer KA, Brcic M, Jungi TW: Toll-like receptor-4 is involved in eliciting an LPS-induced oxidative burst in neutrophils. Immunol Lett 2002;85(1):75–80. Netea MG, van der Graaf C, Van der Meer JWM, Jan-Kullberg B: Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. J Leukoc Biol 2004;75(5):749–755. Lambrecht BN, Prins JB, Hoogsteden HC: Lung dendritic cells and host immunity to infection. Eur Respir J 2001;18(4):692–704. Sinigaglia F, D'Ambrosio D: Regulation of helper T cell differentiation and recruitment in airway inflammation. Am J Respir Crit Care Med 2000;162(4):175S-160. Woo JS, Jeong JY, Hwang YJ, et al.: Expression of cathelicidin in human salivary glands. Arch Otolaryngol Head Neck Surg 2003;129(2):211–214. van der Reijden WA, Vissink A, Veerman ECI, Amerongen AVN: Treatment of oral dryness related complaints (xerostomia) in Sjogren's syndrome. Ann Rheum Dis 1999;58(8):465–474. Dale BA, Kimball JR, Krisanaprakornkit S, et al.: Localized antimicrobial peptide expression in human gingiva. J Periodontal Res 2001;36(5):285–294. Celis R, Torres A, Gatell JM, et al.: Nosocomial pneumonia. A multivariate analysis of risk and prognosis. Chest 1988;93(2):318–324. Kim ST, Cha HE, Kim DY, et al.: Antimicrobial peptide LL-37 is upregulated in chronic nasal inflammatory disease. Acta Otolaryngol 2003;123(1):81–85. Smith JJ, Travis SM, Greenberg E, Welsh MJ: Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996;85(2):229–236. Goldman MJ, Anderson GM, Stolzenberg ED, et al.: Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997;88(4):553–560. Kennedy MJ: Current status of gene therapy for cystic fibrosis pulmonary disease. Am J Respir Med 2002; 1(5):349–360. Bals R, Weiner DJ, Meegalla RL, Wilson JM: Transfer of a cathelicidin peptide antibiotic gene restores bacterial killing in a cystic fibrosis xenograft model. J Clin Invest 1999;103(8):1113–1117. Schaller-Bals S, Schulze A, Bals R: Increased levels of antimicrobial peptides in tracheal aspirates of newborn infants during infection. Am J Respir Crit Care Med 2002;165(7):992–995. Agerberth B., Grunewald J, Castanos-Velez, E, et al.: Antibacterial components in bronchoalveolar lavage fluid from healthy individuals and sarcoidosis patients. Am J Respir Crit Care Med 1999;160(1):283–290. Repine JE: Interleukin-1-mediated acute lung injury and tolerance to oxidative injury. Environ Health Perspect 1994;102 Suppl. 10:75–78. Fahy RJ, Elssner A, Wewers MD: The antimicrobial peptide LL-37/hCAP-18 is elevated in early ARDS. Am J Respir Crit Care. Med 2003;167(7):A759. Toney JH: Iseganan (IntraBiotics pharmaceuticals). Curr Opin Invest Drugs 2002;3(2):225–228. Cole AM, Waring AJ: The role of defensins in lung biology and therapy. Am J Respir Med 2002;1(4):249–259. Warren HS, Matyal R, Allaire JE, et al.: Protective efficacy of CAP18106-138-immunoglobulin G in sepsis. J Infect Dis 2003;188(9):1382–1393. Gennaro R, Scocchi M, Merluzzi L, Zanetti M: Biological characterization of a novel mammalian antimicrobial peptide. Biochim Biophys Acta 1998;1425(2):361–368. Lusitani D, Malawista SE, Montgomery RR: Borrelia burgdorferi are susceptible to killing by a variety of human polymorphonuclear leukocyte components. J Infect Dis 2002;185(6):797–804. Larrick JW, Morgan JG, Palings I, et al.: Complementary DNA sequence of rabbit CAP18: a unique lipopolysaccharide binding protein. Biochem Biophys Res Commun 1991;179(1):170–175. Nagaoka I, Hirota S, Niyonsaba F, et al.: Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-α by blocking the binding of LPS to CD14+Cells. J Immunol 2001;167(6):3329–3338.